# Vima Therapeutics

> Vima Therapeutics is a Cambridge, Massachusetts clinical-stage biotechnology company developing VIM0423, a potential first-in-class once-daily oral therapy for isolated dystonia and Parkinson's disease. The drug selectively targets muscarinic cholinergic receptors in the brain to correct the dopamine-acetylcholine imbalance underlying these movement disorders. Incubated at Atlas Venture and led by neurologist Bernard Ravina, the company emerged from stealth in 2025 and has raised a $100 million Series A.

- **Founded:** 2023
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Bernard Ravina (Founder & CEO)
- **Team size:** ~22 employees
- **Products:** VIM0423, Stride Dystonia (Phase 2 trial)
- **Notable:** Raised a $100 million Series A (initial $60M plus $40M extension), Advanced VIM0423 into Phase 2 with first dystonia patient dosed (March 2026), Received FDA Fast Track designation for VIM0423 in isolated dystonia

## Products & services

- **VIM0423** — A potential first-in-class, once-daily oral therapy that selectively targets muscarinic cholinergic receptors in the brain to correct the dopamine-acetylcholine imbalance underlying isolated dystonia and Parkinson's disease. Granted FDA Fast Track designation for isolated dystonia.
- **Stride Dystonia (Phase 2 trial)** — Vima's Phase 2 clinical study of VIM0423 in isolated dystonia; first patient dosed in March 2026, with topline data expected in the first half of 2027.

## Achievements

- Raised a $100 million Series A (initial $60M plus $40M extension)
- Advanced VIM0423 into Phase 2 with first dystonia patient dosed (March 2026)
- Received FDA Fast Track designation for VIM0423 in isolated dystonia
- Emerged from stealth in May 2025 with a potential first-in-class oral therapy

## Latest updates

- **2026-03** — Announced first dystonia patient dosed in Phase 2 Stride trial and extension of Series A to $100 million with new investor Frazier Life Sciences.
- **2025-05** — Launched out of stealth with $60 million Series A led by Atlas Venture to advance VIM0423 for dystonia and movement disorders.

## Links

- Website: https://vimatx.com
- LinkedIn: https://www.linkedin.com/company/vima-therapeutics

---

Profile page: https://yespress.io/vima-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-10